DOCSLIB.ORG

Subject Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Subject Index A N-Acetyl H Acid, 3:923 Abietane, 3:1187 see also 4–Acetylamino–5–hydroxynaphthalene–2,7–disulfonic acid Absorption N-Acetyl J acid, 3:919 of nitroaniline-based dyes, 3:989 see also 7–Acetamido–4–hydroxynaphthalene–2–sulfonic acid Accelerator TMTD, 2:617 Acetylthiophene, 3:1247 ACCEL EZ, 2:615 2-Acetylthiophene [88-15-3], 3:1245, 1246 ACCEL PX, 2:616 toxicology, 3:1251 ACCEL PZ, 2:615 A Acid, 3:874, 7-disulfonic acid ACCEL SDD, 2:615 see also 3,5-Dihydroxynaphthalene-2 ACCEL TMT, 2:617 B Acid, 3:874, 6, 8-trisulfonic acid ACCEL TS, 2:616 see also 1-Aminonaphthalene-4 Acetaldehyde (ethanal) C Acid (Cassella acid), 3:874 glyoxal from, 2:653 see also 2-Aminonaphthalene-4, 8-disulfonic acid 6-Acetamido-4-hydroxynaphthalene-2-sulfonic acid, 3:921 D Acid, 3:874 N–Acetyl g Acid see also Dahl’s Acid; 2-Aminonaphthalene-5-sulfonic acid 7-Acetamido-4-hydroxynaphthalene-2-sulfonic acid, 3:919 F Acid, 3:874 see also N–Acetyl J acid see also 2-Hydroxynaphthalene-7-sulfonic acid Acetic acid, 2:476, G Acid, 3:874 chlorination, 2:803 2-Hydroxynaphthalene-6,8-disulfonic acid ketene and acetic anhydride from, 2:803, 804 J Acid, 3:874 Acetic anhydride see also 2-Amino-5-hydroxynaphthalene-7-sulfonic acid from methyl acetate, 2:804 L Acid (Laurent’s acid), 3:874 Acetic chloroacetic anhydride, 2:475 see also 1-Aminonaphthalene-5-sulfonic acid Acetoacetalkylamide, 2:810 M Acid, 3:874 Acetoacetamide, 2:810, 3:1017 see also 1-Amino-5-hydroxynaphthalene-7-sulfonic acid toxicology, 3:1019 R Acid, 3:874 Acetoacetanilide, 2:811 see also 2-Hydroxynaphthalene-3, 6-disulfonic acid Acetoacetarylamides, 2:810 RG Acid (Violet acid), 3:874 Acetoacetates (esters), 2:809, 3:1017 see also 1-Hydroxynaphthalene-3, 6-disulfonic acid Acetoacetic acid, 3:1017, 1020 RM Acid, 3:874 keto–enol forms, 3:1017 see also 2-Amino-3-hydroxynaphthalene-6-sulfonic acid Acetoacetoxyethyl methacrylate, 2:811 S Acid, 3:874 Acetoacetylation, 2:807 see also 1-Amino-8-hydroxynaphthalene-4-sulfonic acid a-Acetobutyrolactone, 1:392 T Acid, 3:874, 6, 8-trisulfonic acid Acetone (2-propanone) (DMK) see also 1-Aminonaphthalene-3 ketene from, 2:804 d Acid, 3:874, 8-disulfonic acid Acetonedicarboxylic acid, 3:1020 see also 1-Hydroxynaphthalene-4 see also 3-Oxopentane dicarboxylic acid e Acid, 3:874, 8-disulfonic acid toxicology, 3:1021 see also 1-Hydroxynaphthalene-3 Acetonitrile, 3:937 H Acid (8-Amino-1-hydroxynaphtalene-3,6-disulfonic acid), 3:874 Acetophenone, 2:832 see also 1-Amino-8-hydroxynaphthalene-3, 6-disulfonic acid see also Methyl phenyl ketone K Acid (8-Amino-1-hydroxynaphtalene-3,5-disulfonic acid), 3:874 4-Acetoxybutyraldehyde, 1:77 see also 1-Amino-8-hydroxynaphthalene-4, 6-disulfonic acid Acetylacetone, 2:805 g Acid (7-Amino-1-hydroxynaphthalene-3-sufonic acid), 3:874 see also 2,4–Pentanedione see also 2-Amino-8-hydroxynaphthalene-6-sulfonic acid 2,4-Pentanedione, 2:830 Acid Black 36, 3:905 Acetylacetonitrile, 3:940 Acid Black 52, C.I. 15711, 3:917 see also b-Ketobutyronitrile Acid Blue 61, 3:908 N-Acetyl g Acid Acid Blue 113, C.I. 26360, 3:897, 906 see also 6–Acetamido–4–hydroxynaphthalene–2–sulfonic Acid Blue 158, 3:890 acid, 3:921 Acid Brown 43, 3:881 4-(Acetylamino)benzenesulfonamide, 1:263 Acid desulfonation 4-(Acetylamino)benzenesulfonic acid, 1:263 of hydroxynaphthalenedi- and trisulfonic acids, 3:888 4-(Acetylamino)benzenesulfonyl chloride, 1:263 Acidol, 1:201 5-Acetylamino-2-hydroxybenzenesulfonic acid, 1:271 Acid Orange 7, C.I. 15510, 3:883 4-Acetylamino-5-hydroxynaphthalene-2,7-disulfonic acid, 3:923 Acid Orange 20, 3:881 see also N–Acetyl H Acid Acid Red 7, 3:892 3-Acetylamino-4-methoxybenzenesulfonamide, 1:270 Acid Red 25, 3:892, 904 3-Acetylamino-4-methoxybenzenesulfonyl chloride, 1:270 Acid Red 26, 3:978 3-Acetylamino-4-methoxy-N-methylbenzenesulfonamide, 1:270 Acid Red 33, 3:922 4-(Acetylaminomethyl)benzenesulfonamide, 1:257 Acidrine, 1:202 4-(Acetylaminomethyl)benzenesulfonyl chloride, 1:257 Acid Violet 90, 3:916 2-Acetylamino-5-nitrothiazole, 3:1008 NW Acid (Nevile and Winther acid), 3:874 Acetylation by ketene, 2:802 see also 1-Hydroxynaphthalene-4-sulfonic acid N-Acetylcysteine 1:200, 3:1218 Acinitrazole, 3:1010 N-Acetyl-3,30-dichlorobenzidine, 1:288 Aciventral, 1:201 Acetylenecarboxylic acid, 2:440, 444 Acrolein (propenal) Acetylenediurea (Tetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione) hydrogenation or reduction to allyl alcohol, 1:76 [496-46-8], 3:1281 Acrylonitrile (acrylic acid nitrile) Ullmann’s Fine Chemicals Ó 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany ISBN: 978-3-527-33477-3 / DOI: 10.1002/14356007 1292 Acthiol – Amine boranes Index reaction with amines to di- and polyamines, 1:117 of phenols, 3:1042 Acthiol, 1:204 Alkylbenzenesulfonates (ABS) Acyclic diterpenes, 3:1197 alkylphenols from, 3:1046 Acyclic monoterpenes, 3:1189 Alkyl disulfides Acyclic triterpenes, 3:1197 production of, 3:1221 Acyclovir, 3:1134 Alkyl dithiophosphates, 3:1121 2-Acyliminothiazolidines, 2:611 a,a-Alkyleneureas, 3:1279 Acyloins, cyclic, 2:586 1-Alkyl-3-ethylimidazolium trifluoromethanesulfonate salts Acylphenols preparation, 2:746 alkylphenols from, 3:1046 Alkylnaphthalenesulfonic acids, 3:879 Adamantane, 2:574 Alkylphenols, 3:1037 Adenine, 3:1132 higher, transportation and classification, 3:1064 Adipic acid, 2:585 separation from cracking fractions, 3:1041 see also Hexanedioic acid toxicology, 3:1064 reduction to 1,6-hexanediol, 1:45 Alkyl phosphonates, 3:1113 sebacic acid from, 2:589 Alkyl polysulfides Adrogolide, 3:1247 production of, 3:1221 Aerofine 3418 A, 3:1102 Alkyl sulfides Aerofloat, 3:1121, 1122 production of, 3:1220 Aerophine 3418 A, 3:1111 Alkylthiophenes, 3:1249 Agar Allicin, 3:1160 nutrient, minimum inhibitory concentration (MIC) of halogenated phenol Allyl acetate, 1:76, 77, 79 derivatives in, 3:1085 allyl alcohol from, 1:76 Agrisil, 3:1116 toxicology, 1:84 Agrochemicals Allyl acrylate, 1:78 amino acids in, 1:205 polymers and copolymers of, 1:81 fine chemicals, 1:26 Allyl alcohol, 1:73 Airol, 2:721 toxicology, 1:84 Akrochem ETU-22, 3:1262 Allylamine, 1:82, 115 Aktiferrin, 1:203 in 2-pyrrolidone production, 3:1138 Aktivanad, 1:202 toxicology, 1:85 D-Alanine, 1:173 Allyl bromide, 1:376 D,L-Alanine, 1:173 see also 3-Bromo-1-propene L-Alanine, 1:167, 171, 201, 3:1015, 1016 Allyl chloride, 1:67 production, 1:179 dispersion of, 2:512 b-Alanine, 1:173 epichlorohydrin from, 2:638 Alanine as flavor enhancer, 1:195 toxicology, 1:83 Albrite, 3:1119 Allyl chloroformate, 2:498 Alcohols Allyl compounds, 1:67 amines from, 1:117 Allyl cyanoacetate, 2:857 carboxylic acids by alkali fusion, 2:440 Allyl esters, 1:77 electrochemical oxidative carbonylation of, 1:415 polymers and copolymers of, 1:80 ionic liquids in chlorination of, 2:751 toxicology, 1:84 long-chain alcohols via triethylaluminum, 1:100 Allyl ethers, 1:82 oxidative carbonylation of, 1:411 Allyl ethyl ether oxidative carbonylation with NOx, 1:414 toxicology, 1:85 reaction with urea, 1:415 Allyl glycidyl ether, 1:82 Alcohols, polyhydric, 1:37 toxicology, 1:84 Aldehydes Allyl isothiocyanate, 3:1206, 1209, 1210, aliphatic, 1:59 Allyl methacrylate, 1:78 araliphatic, 1:59 polymers and copolymers of, 1:81 bisphenols from, 3:1077 toxicology, 1:84 oxidation to carboxylic acids, 2:438 Allyl methallyl ether, 1:75 polyhydric alcohols from, 1:40 5-[(Allyloxi)methyl]-5-ethyl-1,3-dioxan-2-one, 1:409 Aldoketenes, 2:811 4-Allylphenol, 3:1041 Aldol condensation see also Chavicol aldehyde production, 1:60 Allyl vinyl ether Aldomet toxicology, 1:85 see also Methyl DOPA, 3:961 Alphamin, 3:899 Alen acid, 3:913 see also 1,5–Naphthalenediamine; 1, 5–Diaminonaphthalene see also 4,5–Diaminonaphthalene–2,7–sulfonic acid Alphol, 3:880 Al-Glycin, 1:202 see also 1–Naphthyl salicylate Aliette, 3:1113 Aluminium compound, organic Alkali fusion toxicology, 1:108 of benzenesulfonic acids, 1:242 Aluminoxane, 1:102 of naphthalenesulfonic acids, 3:887 Aluminum alkoxide Alkanes by exothermic radical chain mechanism, 1:94 oxidation to carboxylic acids, 2:440 Aluminum compounds, organic, 1:91 Alkenes Aluminum hydride (alane), 2:688 polyhydric alcohols from, 1:39 g-Aluminum oxide Alkenylphenols, 3:1066 for ortho-alkylation of phenols, 3:1044 Alkoxyalanates, 2:690 Aluminum phenolates a-Alkoxyalkylureas, 3:1278 for ortho-alkylation of phenols, 3:1043 Alkylaluminum alkoxide Alumnol, 3:894 from alkylaluminum compounds, 1:95 Amanita phalloides, 3:1225 Alkylaluminum compounds, 1:92, 93 Amberlite JR-112, 3:1042 Alkylammonium halide Amgard, 3:1116, 1118 preparation, 2:745 Amido F acid, 3:906 Alkyl aryl phosphates, 3:1118 see also 2–Aminonaphthalene–7–sulfonic acid Alkyl aryl phosphites, 3:1112, 1113 Amine, aliphatic Alkylation toxicology, 1:151 with aliphatic nitro compounds, 3:957 Amine boranes, 1:355 of amines, 1:116 (C2H5)3NÁBH3, 1:355 Vol. 1 to 3 Amines – 2-Amino-5-hydroxynaphthalene-7-sulfonic 1293 (CH3)3NÁBH3, 1:355 4-Amino-5-chloro-3-methylbenzenesulfonic acid, 1:273 1 2 (C2H5)2NHÁBH3, 1:355 4-Amino-6-chloro-N ,N -dimethyl-1,3-benzene-disulfonamide, 1:272 (CH3)2NHÁBH3, 1:355 2-Amino-4-chlorophenol, 3:1004 C4H9NH2ÁBH3, 1:355 2-Amino-6-chlorotoluene-4-sulfonic acid, 3:1002 morpholine borane, 1:355 4-Amino-6-chlorotoluene-3-sulfonic acid, 3:987 pyridine borane, 1:355 3-Aminocrotonate esters, 2:811 toxicology, 1:363 2-Aminocyanoacetamide, 2:857 Amines 1-Amino-3-cyclohexylaminopropane, 1:146 acylation with carbamoyl chlorides, 3:1275 Aminocyclopentane, 1:126 phosgenation, 3:1274 see Cyclopentylamine reaction with cyanates, 3:1275 2-Amino-4,5-dichlorobenzenesulfonamide, 1:272 reaction with isocyanates, 3:1275
Recommended publications
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition

    Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition

    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
  • Hygroscopicity of Pharmaceutical Crystals

    Hygroscopicity of Pharmaceutical Crystals

    HYGROSCOPICITY OF PHARMACEUTICAL CRYSTALS A DISSERTATION SUBMITTED TO THE FACULTY OF GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY DABING CHEN IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY RAJ SURYANARAYANAN (ADVISER) JANUARY, 2009 © Dabing Chen, January / 2009 ACKNOWLEDGEMENTS I am very grateful to my thesis advisor, Prof. Raj Suryanarayanan, for his constant guidance, support, and encouragement throughout my research. Without his help, the completion of this thesis would be impossible. His friendship and advices are precious to my professional and personal growth and will help me overcome many difficulties in my future career. I would like to take the opportunity to thank Prof. David J.W. Grant, who was my advisor during the first three years in graduate school and led me into the research area of physical pharmacy. It was my great honor to have worked for him, and he will always live as a role model in my life. Many thanks to Dr. Zheng Jane Li at Boehringer Ingelheim Pharmaceuticals (BI) for her invaluable advice as an industrial mentor and also for agreeing to serve on my committee. I sincerely appreciate her helpful discussions, revision of the manuscripts, and supervision of my research. I also want to thank her for providing me the internship opportunity at BI. I thank Dr. Timothy S. Wiedmann and Dr. Theodore P. Labuza for serving on my committee and for critically reviewing my thesis. I also want to thank Dr. Timothy S. Wiedmann for allowing me the use of the HPLC instruments in his lab and also for his advice as the Director of Graduate Studies.
  • Chapter 1 Tropone and Tropolone

    Chapter 1 Tropone and Tropolone

    School of Molecular and Life Sciences New Routes to Troponoid Natural Products Jason Matthew Wells This thesis is presented for the Degree of Doctor of Philosophy of Curtin University November 2018 Declaration To the best of my knowledge and belief this thesis contains no material previously pub- lished by any other person except where due acknowledgement has been made. This thesis contains no material which has been accepted for the award of any other degree or diploma in any other university. Signature: Date: i Abstract Malaria is an infectious disease found in humans and other animals, it is caused by a single-cell parasite of the Plasmodium genus with many different substrains. Of these, P. falciparum is the most deadly to humans causing the majority of deaths. Although research into the area of antimalarial compounds is wide spread, few have been devel- oped with new structural features. Cordytropolone 37 is a natural product isolated in 2001 from the insect pathogenic fungus Cordyceps sp. BCC 1681 and has been shown to have antimalarial activity against P. falciparum. It has a structure unrelated to antimalarial com- pounds currently used in therapy. It does not contain a peroxide bridge as with artemisinin 25 or quinoline rings as with chloroquine 22. This unique structure indicates that it could possibly interact with the malaria parasite in a fashion unlike current treatments. In order for cordytropolone to be further developed as a potential treatment, it must first be synthe- sised in a laboratory environment. This study attempts to develop the first total synthesis of cordytropolone. H HO O N O O N O N H H H O O Cl HO O 22 25 37 Figure 0.0.1: Cordytropolone 37 has a unique structure compared to the current common malaria treatments The first method investigated towards the total synthesis of cordytropolone involved an intramolecular Buchner ring expansion.
  • Alkyl Halides Work Best; Secondary Alkyl Halides Give Lower Yields

    Alkyl Halides Work Best; Secondary Alkyl Halides Give Lower Yields

    CHAPTER 21 ESTER ENOLATES ou have already had considerable experience with carbanionic compounds and their applications in synthetic organic chemistry. The first was acetylide ion in YChapter 9, followed in Chapter 14 by organometallic compounds—Grignard reagents, for example—that act as sources of negatively polarized carbon. In Chapter 18 you learned that enolate ions—reactive intermediates generated from aldehydes and ketones—are nucleophilic, and that this property can be used to advantage as a method for carbon–carbon bond formation. The present chapter extends our study of carbanions to the enolate ions derived from esters. Ester enolates are important reagents in synthetic organic chemistry. The stabilized enolates derived from ␤-keto esters are particularly useful. OO C ␣ C ␤ R CH2 ORЈ ␤-Keto ester: a ketone carbonyl is ␤ to the carbonyl group of the ester. A proton attached to the ␣-carbon atom of a ␤-keto ester is relatively acidic. Typical Ϫ11 acid dissociation constants Ka for ␤-keto esters are Ϸ10 (pKa 11). Because the ␣- carbon atom is flanked by two electron-withdrawing carbonyl groups, a carbanion formed at this site is highly stabilized. The electron delocalization in the anion of a ␤-keto ester is represented by the resonance structures 831 832 CHAPTER TWENTY-ONE Ester Enolates Ϫ Ϫ O O O O O O C C C C C C R C ORЈ R ϪC ORЈ R C ORЈ H H H Principal resonance structures of the anion of a ␤-keto ester We’ll begin by describing the preparation and properties of ␤-keto esters, proceed to a discussion of their synthetic applications, continue to an examination of related species, and conclude by exploring some recent developments in the active field of synthetic car- banion chemistry.
  • Landolt-Börnstein Indexes of Organic Compounds Subvolumes A-I by V

    Landolt-Börnstein Indexes of Organic Compounds Subvolumes A-I by V

    Landolt-Börnstein Indexes of Organic Compounds Subvolumes A-I By V. Vill, C. Bauhofer, G. Peters, H. Sajus, P. Weigner, LCI-Publisher and Chemistry Department of the University of Hamburg All printed index material has been used to build up the comprehensive Scidex database index developed by LCI Publisher GmbH, Hamburg For further information please visit www.lci-publisher.com From this database a CD-ROM and two online versions were derived. The first is attached to each of the printed subvolumes and the latter are offered for free use at the following addresses: Scidex Database online with graphical structure search on http://lb.chemie.uni-hamburg.de/ Or the easy to use html version on http://lb.chemie.uni-hamburg.de/static/ Landolt-Börnstein Numerical Data and Functional Relationships in Science and Technology New Series / Editor in Chief: W. Martienssen Index of Organic Compounds Subvolume A Compounds with 1 to 7 Carbon Atoms Editor: V. Vill Authors: V. Vill, G. Peters, H. Sajus 1 3 ISBN 3-540-66203-0 Springer-Verlag Berlin Heidelberg New York Library of Congress Cataloging in Publication Data Zahlenwerte und Funktionen aus Naturwissenschaften und Technik, Neue Serie Editor in Chief: W. Martienssen Index of Organic Compounds A: Editor: V. Vill At head of title: Landolt-Börnstein. Added t.p.: Numerical data and functional relationships in science and technology. Tables chiefly in English. Intended to supersede the Physikalisch-chemische Tabellen by H. Landolt and R. Börnstein of which the 6th ed. began publication in 1950 under title: Zahlenwerte und Funktionen aus Physik, Chemie, Astronomie, Geophysik und Technik.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • Partial Agreement in the Social and Public Health Field

    Partial Agreement in the Social and Public Health Field

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol

    (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol

    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
  • (12) United States Patent (10) Patent No.: US 8.242,110 B2 Deregnaucourt Et Al

    (12) United States Patent (10) Patent No.: US 8.242,110 B2 Deregnaucourt Et Al

    USOO824211 OB2 (12) United States Patent (10) Patent No.: US 8.242,110 B2 Deregnaucourt et al. (45) Date of Patent: Aug. 14, 2012 (54) USE OF ANTIHISTAMINEAGENTS FOR THE FOREIGN PATENT DOCUMENTS PREVENTIVE OR EARLY TREATMENT OF FR 2802 101 A1 6, 2001 INFLAMMATORY SYNDROMES, IN JP 4-89428 A 3, 1992 PARTICULAR THOSE TRIGGERED BY JP 2001-151677 A 6, 2001 TOGAVIRUSES WO WO-96,04787 A1 2, 1996 (75) Inventors: Jean Deregnaucourt, Paris (FR): OTHER PUBLICATIONS Etienne Andre, Seyssinet-Pariset (FR): Wilson, Annals of Rheumatic Diseases, 1953; 12(1):38-39.* Jacky Tisne-Versailles, Castres (FR) Storms, Journal of Allergy and Clinical Immunology, 2004; 114:S146-153.* (73) Assignee: Pierre Fabre Medicament, Satake et al., Journal of Cardiovascular Pharmacology, Boulogne-Billancourt (FR) 1994:23(4):669-673 (abstract only).* Toovey et al., Travel Medicine and Infectious Disease, vol.2, No. 3-4, (*) Notice: Subject to any disclaimer, the term of this 2004, pp. 189-191. patent is extended or adjusted under 35 Suhrbier et al., Current Opinion in Rheumatology, vol. 16, No. 4. U.S.C. 154(b) by 809 days. 2004, pp. 374-379. Stocks et al., Australian Family Physician, vol. 26, No. 6, Jun. 1997. (21) Appl. No.: 12/224,830 pp. 710-717. Paganin et al., Presse Medicale 2006, vol. 35. No. 4 II, 2006, pp. (22) PCT Filed: Mar. 9, 2007 641-646. Ware et al., Medical Care, vol. 34, No. 3, 1996, pp. 220-233. (86). PCT No.: PCT/EP2007/052237 Bruce et al., The Journal of Rheumatology, vol. 30, No. 1, 2003, pp.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0